How to buy Enanta Pharmaceuticals stock | 45.34

Enanta Pharmaceuticals, Inc is a biotechnology business based in the US. Enanta Pharmaceuticals shares (ENTA) are listed on the NASDAQ and all prices are listed in US Dollars. Enanta Pharmaceuticals employs 132 staff and has a trailing 12-month revenue of around USD$150.2 million.

How to buy shares in Enanta Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Enanta Pharmaceuticals. Find the stock by name or ticker symbol: ENTA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Enanta Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$45.34, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Enanta Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Enanta Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Enanta Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Enanta Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$45.34, which is 14.77% down on its pre-crash value of USD$53.2 and 18.07% up on the lowest point reached during the March crash when the shares fell as low as USD$38.4.

If you had bought USD$1,000 worth of Enanta Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$869.91 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$858.74.

Enanta Pharmaceuticals share price

Use our graph to track the performance of ENTA stocks over time.

Enanta Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$45.34
52-week range	USD$38.4 - USD$65.755
50-day moving average	USD$46.4056
200-day moving average	USD$49.7218
Wall St. target price	USD$67.57
PE ratio	447.3
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.119

Buy Enanta Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Enanta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Enanta Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enanta Pharmaceuticals price performance over time

Historical closes compared with the close of $45.34 from 2020-11-16

1 week (2020-11-18)	2.60%
1 month (2020-10-23)	3.40%
3 months (2020-08-25)	-10.47%
6 months (2020-05-22)	-18.01%

1 year (2019-11-25)	-27.68%
2 years (2018-11-23)	-42.60%
3 years (2017-11-24)	-5.27%
5 years (2015-11-25)	41.69%

Is Enanta Pharmaceuticals under- or over-valued?

Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enanta Pharmaceuticals's P/E ratio

Enanta Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 447x. In other words, Enanta Pharmaceuticals shares trade at around 447x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Enanta Pharmaceuticals's EBITDA

Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.8 million.

The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Enanta Pharmaceuticals financials

Revenue TTM	USD$150.2 million
Gross profit TTM	USD$205.2 million
Return on assets TTM	-1.96%
Return on equity TTM	0.51%
Profit margin	1.57%
Book value	$23.944
Market capitalisation	USD$873.3 million

TTM: trailing 12 months

Shorting Enanta Pharmaceuticals shares

There are currently 2.1 million Enanta Pharmaceuticals shares held short by investors – that's known as Enanta Pharmaceuticals's "short interest". This figure is 2.8% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Enanta Pharmaceuticals shares can be evaluated.

Enanta Pharmaceuticals's "short interest ratio" (SIR)

Enanta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Enanta Pharmaceuticals shares currently shorted divided by the average quantity of Enanta Pharmaceuticals shares traded daily (recently around 194417.74042951). Enanta Pharmaceuticals's SIR currently stands at 10.71. In other words for every 100,000 Enanta Pharmaceuticals shares traded daily on the market, roughly 10710 shares are currently held short.

However Enanta Pharmaceuticals's short interest can also be evaluated against the total number of Enanta Pharmaceuticals shares, or, against the total number of tradable Enanta Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enanta Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Enanta Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1269% of the tradable shares (for every 100,000 tradable Enanta Pharmaceuticals shares, roughly 127 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Enanta Pharmaceuticals.

Find out more about how you can short Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals share dividends

We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.

Enanta Pharmaceuticals share price volatility

Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $38.4 up to $65.755. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.4231. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).

Enanta Pharmaceuticals overview

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

• What percentage of Enanta Pharmaceuticals is owned by insiders or institutions?

  Currently 11.537% of Enanta Pharmaceuticals shares are held by insiders and 92.196% by institutions.

• How many people work for Enanta Pharmaceuticals?

  Latest data suggests 132 work at Enanta Pharmaceuticals.

• When does the fiscal year end for Enanta Pharmaceuticals?

  Enanta Pharmaceuticals's fiscal year ends in September.

• Where is Enanta Pharmaceuticals based?

  Enanta Pharmaceuticals's address is: 500 Arsenal Street, Watertown, MA, United States, 02472

• What is Enanta Pharmaceuticals's ISIN number?

  Enanta Pharmaceuticals's international securities identification number is: US29251M1062

• What is Enanta Pharmaceuticals's CUSIP number?

  Enanta Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 29251M106